Rebimastat

Rebimastat
Clinical data
Other namesBMS-275291
Routes of
administration		By mouth
Identifiers
  • (2S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H41N5O5S
Molar mass499.67 g·mol−1
3D model (JSmol)
  • CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C
  • InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-16(19(31)24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,34H,10-12H2,1-9H3,(H,24,31)(H,25,30)(H,26,29)/t14-,15-,16+/m0/s1
  • Key:GTXSRFUZSLTDFX-HRCADAONSA-N

Rebimastat is an abandoned investigational antineoplastic drug developed as a broad-spectrum matrix metalloproteinase inhibitor (MMPI). It was designed to target enzymes implicated in cancer progression, aiming to reduce tumor growth and metastasis. Although promising in preclinical studies, clinical development was halted due to adverse effects.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.